Based on several clinical trials, the US Food and Drug Administration (FDA) has approved two subcutaneous GLP1-RAs, liraglutide (3 mg once daily) and semaglutide (2.4 mg once weekly), as weight loss medications for long-term use in individuals with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with at least one weight-associated comorbidity, regardless of T2DM status [59]. Here, GCG is linked to type 2 diabetes mellitus.